Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H107e + CAF10b
- Development stage
- Phase 1
- Lead developer
- Statens Serum Institut
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
H107e + CAF10b is a next-generation tuberculosis (TB) subunit vaccine candidate developed by Statens Serum Institut. It consists of the recombinant protein antigen H107e, which incorporates eight different Mycobacterium tuberculosis (Mtb) antigens—including ESAT-6 repeated four times—formulated with the novel liposomal adjuvant CAF10b. The adjuvant is designed to induce strong Th1 and Th17 immune responses, enhancing T cell-mediated immunity against Mtb. The vaccine aims to complement or boost Bacillus Calmette–Guérin (BCG) vaccination by introducing new T cell specificities not targeted by BCG, and it can be co-administered with BCG for synergistic protection. The primary indication is prevention of TB disease in adolescents, adults, infants, people living with HIV, and both Mtb-infected and uninfected individuals. Administration is intramuscular[2][4][5][7].
- Other names
- H107e/CAF®10bH107e/CAF10b vaccine
02
Targets
TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on H107e + CAF10b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H107e + CAF10b.